Therapeutic efficacy and prognostic indicators in re-resection for recurrent hepatocellular carcinoma: Insights from a retrospective study

Aims: To evaluate the efficacy of re-resection in recurrent hepatocellular carcinoma (rHCC), identify prognostic factors, and provide clinical guidance. Methods: A retrospective analysis was conducted on 130 rHCC patients undergoing re-resection and 60 primary HCC patients undergoing initial hepatec...

Full description

Saved in:
Bibliographic Details
Main Authors: Qi Fan, MM, Pengcheng Wei, MM, Delin Ma, MD, Qian Cheng, MD, Jie Gao, MD, Jiye Zhu, MD, Zhao Li, MD
Format: Article
Language:English
Published: Elsevier 2025-01-01
Series:Surgery Open Science
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2589845024001404
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832576439490183168
author Qi Fan, MM
Pengcheng Wei, MM
Delin Ma, MD
Qian Cheng, MD
Jie Gao, MD
Jiye Zhu, MD
Zhao Li, MD
author_facet Qi Fan, MM
Pengcheng Wei, MM
Delin Ma, MD
Qian Cheng, MD
Jie Gao, MD
Jiye Zhu, MD
Zhao Li, MD
author_sort Qi Fan, MM
collection DOAJ
description Aims: To evaluate the efficacy of re-resection in recurrent hepatocellular carcinoma (rHCC), identify prognostic factors, and provide clinical guidance. Methods: A retrospective analysis was conducted on 130 rHCC patients undergoing re-resection and 60 primary HCC patients undergoing initial hepatectomy at Peking University People's Hospital (2014–2022). Disease-free survival (DFS) and overall survival (OS) were compared. Prognostic factors were identified using univariate and multivariate COX regression analyses. Results: Baseline characteristics were comparable between groups (P > 0.05). DFS was similar between groups (30.8 vs. 32.2 months, P = 0.612). The 1-year, 2-year, and 3-year DFS rates for the re-resection group were 88.5 %, 64.9 %, and 56.7 %, respectively, versus 88.3 %, 65.0 %, and 53.3 % for the primary resection group. OS was lower in the re-resection group (36.1 vs. 47.2 months, P = 0.041) with 1-year, 2-year, and 3-year OS rates of 90.8 %, 73.1 %, and 60.0 %, compared to 95.0 %, 80.0 %, and 68.3 % for the primary resection group. Significant factors affecting DFS were Child-Pugh classification (P = 0.044), time to recurrence (P = 0.002), tumor differentiation (P = 0.044), and satellite nodules (P = 0.019). Factors influencing OS included Child-Pugh classification (P = 0.040), time to recurrence (P = 0.002), and tumor differentiation (P = 0.032). Conclusions: Re-resection is an effective treatment option for rHCC, with favorable outcomes as measured by DFS and OS, though OS is lower compared to initial hepatectomy. Key prognostic factors include Child-Pugh classification, time to recurrence, tumor differentiation, and satellite nodules.
format Article
id doaj-art-ccc8486fc3214dbab94a20d7eb41ec7c
institution Kabale University
issn 2589-8450
language English
publishDate 2025-01-01
publisher Elsevier
record_format Article
series Surgery Open Science
spelling doaj-art-ccc8486fc3214dbab94a20d7eb41ec7c2025-01-31T05:12:14ZengElsevierSurgery Open Science2589-84502025-01-01231623Therapeutic efficacy and prognostic indicators in re-resection for recurrent hepatocellular carcinoma: Insights from a retrospective studyQi Fan, MM0Pengcheng Wei, MM1Delin Ma, MD2Qian Cheng, MD3Jie Gao, MD4Jiye Zhu, MD5Zhao Li, MD6Department of General Surgery, Beijing Jishuitan Hospital, Capital Medical University, Beijing, ChinaDepartment of Hepatobiliary Surgery, Peking University People's Hospital, Beijing, China; Beijing Key Surgical Basic Research Laboratory of Liver Cirrhosis and Liver Cancer, Beijing, China; Peking University Center of Liver Cancer Diagnosis and Treatment, Beijing, ChinaDepartment of Hepatobiliary Surgery, Peking University People's Hospital, Beijing, China; Beijing Key Surgical Basic Research Laboratory of Liver Cirrhosis and Liver Cancer, Beijing, China; Peking University Center of Liver Cancer Diagnosis and Treatment, Beijing, ChinaDepartment of Hepatobiliary Surgery, Peking University People's Hospital, Beijing, China; Beijing Key Surgical Basic Research Laboratory of Liver Cirrhosis and Liver Cancer, Beijing, China; Peking University Center of Liver Cancer Diagnosis and Treatment, Beijing, ChinaDepartment of Hepatobiliary Surgery, Peking University People's Hospital, Beijing, China; Beijing Key Surgical Basic Research Laboratory of Liver Cirrhosis and Liver Cancer, Beijing, China; Peking University Center of Liver Cancer Diagnosis and Treatment, Beijing, China; Peking University Institute of Organ Transplantation, Beijing, ChinaDepartment of Hepatobiliary Surgery, Peking University People's Hospital, Beijing, China; Beijing Key Surgical Basic Research Laboratory of Liver Cirrhosis and Liver Cancer, Beijing, China; Peking University Center of Liver Cancer Diagnosis and Treatment, Beijing, China; Peking University Institute of Organ Transplantation, Beijing, ChinaDepartment of Hepatobiliary Surgery, Peking University People's Hospital, Beijing, China; Beijing Key Surgical Basic Research Laboratory of Liver Cirrhosis and Liver Cancer, Beijing, China; Peking University Center of Liver Cancer Diagnosis and Treatment, Beijing, China; Peking University Institute of Organ Transplantation, Beijing, China; Corresponding author at: Department of Hepatobiliary Surgery, Peking University People's Hospital, No.11 Xizhimen South Street, Xicheng District, Beijing 100044, China.Aims: To evaluate the efficacy of re-resection in recurrent hepatocellular carcinoma (rHCC), identify prognostic factors, and provide clinical guidance. Methods: A retrospective analysis was conducted on 130 rHCC patients undergoing re-resection and 60 primary HCC patients undergoing initial hepatectomy at Peking University People's Hospital (2014–2022). Disease-free survival (DFS) and overall survival (OS) were compared. Prognostic factors were identified using univariate and multivariate COX regression analyses. Results: Baseline characteristics were comparable between groups (P > 0.05). DFS was similar between groups (30.8 vs. 32.2 months, P = 0.612). The 1-year, 2-year, and 3-year DFS rates for the re-resection group were 88.5 %, 64.9 %, and 56.7 %, respectively, versus 88.3 %, 65.0 %, and 53.3 % for the primary resection group. OS was lower in the re-resection group (36.1 vs. 47.2 months, P = 0.041) with 1-year, 2-year, and 3-year OS rates of 90.8 %, 73.1 %, and 60.0 %, compared to 95.0 %, 80.0 %, and 68.3 % for the primary resection group. Significant factors affecting DFS were Child-Pugh classification (P = 0.044), time to recurrence (P = 0.002), tumor differentiation (P = 0.044), and satellite nodules (P = 0.019). Factors influencing OS included Child-Pugh classification (P = 0.040), time to recurrence (P = 0.002), and tumor differentiation (P = 0.032). Conclusions: Re-resection is an effective treatment option for rHCC, with favorable outcomes as measured by DFS and OS, though OS is lower compared to initial hepatectomy. Key prognostic factors include Child-Pugh classification, time to recurrence, tumor differentiation, and satellite nodules.http://www.sciencedirect.com/science/article/pii/S2589845024001404Recurrent hepatocellular carcinomaRe-resectionPrognosisSurvival analysisImmune microenvironment
spellingShingle Qi Fan, MM
Pengcheng Wei, MM
Delin Ma, MD
Qian Cheng, MD
Jie Gao, MD
Jiye Zhu, MD
Zhao Li, MD
Therapeutic efficacy and prognostic indicators in re-resection for recurrent hepatocellular carcinoma: Insights from a retrospective study
Surgery Open Science
Recurrent hepatocellular carcinoma
Re-resection
Prognosis
Survival analysis
Immune microenvironment
title Therapeutic efficacy and prognostic indicators in re-resection for recurrent hepatocellular carcinoma: Insights from a retrospective study
title_full Therapeutic efficacy and prognostic indicators in re-resection for recurrent hepatocellular carcinoma: Insights from a retrospective study
title_fullStr Therapeutic efficacy and prognostic indicators in re-resection for recurrent hepatocellular carcinoma: Insights from a retrospective study
title_full_unstemmed Therapeutic efficacy and prognostic indicators in re-resection for recurrent hepatocellular carcinoma: Insights from a retrospective study
title_short Therapeutic efficacy and prognostic indicators in re-resection for recurrent hepatocellular carcinoma: Insights from a retrospective study
title_sort therapeutic efficacy and prognostic indicators in re resection for recurrent hepatocellular carcinoma insights from a retrospective study
topic Recurrent hepatocellular carcinoma
Re-resection
Prognosis
Survival analysis
Immune microenvironment
url http://www.sciencedirect.com/science/article/pii/S2589845024001404
work_keys_str_mv AT qifanmm therapeuticefficacyandprognosticindicatorsinreresectionforrecurrenthepatocellularcarcinomainsightsfromaretrospectivestudy
AT pengchengweimm therapeuticefficacyandprognosticindicatorsinreresectionforrecurrenthepatocellularcarcinomainsightsfromaretrospectivestudy
AT delinmamd therapeuticefficacyandprognosticindicatorsinreresectionforrecurrenthepatocellularcarcinomainsightsfromaretrospectivestudy
AT qianchengmd therapeuticefficacyandprognosticindicatorsinreresectionforrecurrenthepatocellularcarcinomainsightsfromaretrospectivestudy
AT jiegaomd therapeuticefficacyandprognosticindicatorsinreresectionforrecurrenthepatocellularcarcinomainsightsfromaretrospectivestudy
AT jiyezhumd therapeuticefficacyandprognosticindicatorsinreresectionforrecurrenthepatocellularcarcinomainsightsfromaretrospectivestudy
AT zhaolimd therapeuticefficacyandprognosticindicatorsinreresectionforrecurrenthepatocellularcarcinomainsightsfromaretrospectivestudy